Changeflow GovPing Pharma & Drug Safety EPO Patent Bulletin: Method for Determining Ant...
Routine Notice Added Final

EPO Patent Bulletin: Method for Determining Anticancer Treatment Efficacy

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Pharma (A61K)
Published March 18th, 2026
Detected March 25th, 2026
Email

Summary

The European Patent Office has published patent application EP4634406A1 detailing a method for determining and improving the potential efficacy of anticancer treatments. The patent application lists ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS and other research institutions as applicants.

What changed

This document is a publication of a European Patent Office (EPO) patent application, EP4634406A1, titled "Method for determining and improving anticancer treatment efficacy." The application was published on March 18, 2026, and lists ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS, Institut National de la Recherche pour l'Agriculture, l'Alimentation et l'Environnement, Université Paris Cité, and Institut National de la Santé et de la Recherche Médicale as applicants.

As this is a patent publication, it does not impose direct compliance obligations or deadlines on regulated entities. However, it signifies a new development in the field of anticancer treatment research and may be of interest to pharmaceutical companies and drug manufacturers for potential licensing, competitive analysis, or future research and development activities.

Source document (simplified)

← EPO Patent Bulletin

METHOD FOR DETERMINING AND IMPROVING THE POTENTIAL EFFICACY OF ANTICANCER TREATMENT

Publication EP4634406A1 Kind: A1 Mar 18, 2026

Applicants

ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS, Institut National de la Recherche pour
l'Agriculture, l'Alimentation et l'Environnement, Université Paris Cité, Institut National de la Santé et de la Recherche
Médicale

Inventors

MICHONNEAU, David, VALLET, Nicolas, LEPAGE, Patricia, LE GOFF, Jérome

IPC Classifications

C12Q 1/6886 20180101AFI20240621BHEP C12Q 1/689 20180101ALI20240621BHEP A61K 31/00 20060101ALI20240621BHEP A23L 33/00 20160101ALI20240621BHEP A61P 31/04 20060101ALI20240621BHEP A61K 35/74 20150101ALI20240621BHEP C12N 7/00 20060101ALI20240621BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

Method for determining and improving anticancer treatment efficacy

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4634406A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Efficacy Testing Cancer Treatment Research
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Research & Development
Compliance frameworks
GxP
Topics
Biotechnology Healthcare Innovation

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.